Get 30% off on all global market reports with code ONLINE30 – stay updated on tariff changes, macroeconomic trends, and more!
Venous Thromboembolism Market Size Expansion: A Snapshot of Growth Between 2024 and 2029
In recent times, the market size for venous thromboembolism has exhibited consistent growth. The market is expected to surge from $2.44 billion in 2024 to a significant $2.53 billion in 2025, showcasing a compound annual growth rate (CAGR) of 3.9%. The increase during the earlier timespan can be credited to factors such as the elderly population, advancements in anticoagulants, favorable reimbursement policies, and escalating investments.
In the upcoming years, the venous thromboembolism market is projected to witness consistent expansion. An increase in the value of $3.02 billion is expected by 2029, with a compound annual growth rate (CAGR) of 4.4%. This growth within the projected period could be due to advances in global healthcare access, genetic risk evaluation, telemedicine and remote monitoring, as well as patient education and support. The forecast period will likely usher in new trends like extended thromboprophylaxis, state-of-the-art oral anticoagulants, bespoke treatment plans, and sophisticated diagnostic imaging.
Claim Your Free Sample Report:
http://www.thebusinessresearchcompany.com/sample….p;type=smp
What Core Factors Are Driving the Expansion of the Venous Thromboembolism Market?
The growth of the venous thromboembolism market is anticipated to be driven by the expansion of healthcare infrastructure. The healthcare industry encompasses the sectors of the economic system offering products and services for patient care, including treatment, prevention, rehabilitation, and palliative care. The growth of this industry helps bolster institutional infrastructure, policies, educational programs, and practices that facilitate the application of VTE prevention protocols.
For example, the American Health Care Association, a US-based nonprofit organization, reported in May 2023 that the number of US hospitals grew to 6,129 from 6,093 in 2022. Moreover, according to the Office for National Statistics, a UK-based statistics authority, the UK’s healthcare expenditure in 2023 was around £292 billion, showing a nominal rise of 5.6%. Also, in 2022, there was a real-terms increase of 2.8% in long-term health and social care expenditure. Hence, the growth of the healthcare industry is propelling the growth of the venous thromboembolism market.
How Is the Venous Thromboembolism Market Structured Across Key Segments?
The venous thromboembolismmarket covered in this report is segmented –
1) By Type: Deep Vein Thrombosis; Pulmonary Embolism; Other Types
2) By Treatment: Anti-Clotting Medications; Mechanical Devices; Thrombolytic Therapy; Other Treatment
3) By End Users: Hospitals; Homecare; Specialty Centers; Other End Users
Subsegments:
1) By Deep Vein Thrombosis (DVT): Proximal DVT; Distal DVT; Asymptomatic DVT
2) By Pulmonary Embolism (PE): Acute PE; Chronic PE; Submassive PE
3) By Other Types: Thrombophlebitis; Superficial Vein Thrombosis; Post-Thrombotic Syndrome
Access the Full Report Today:
http://www.thebusinessresearchcompany.com/report/…ket-report
What Innovation Trends Will Redefine the Venous Thromboembolism Market Landscape?
Key players in the venous thromboembolism market are striving to maintain their dominance by creating innovative anticoagulant medicines and solutions. The progress in anticoagulants indicates the potential for the creation of more effective treatments that can prevent or cure venous thromboembolism. For example, in September 2022, Anthos Therapeutics, an American clinical-stage biotherapeutics firm, attained regulatory clearance for its abelacimab anticoagulant drug from the FAA, a US government organization. The new drug is a fully human monoclonal antibody prescribed for stroke and systemic embolism prevention in atrial fibrillation patients. The novel, once-a-month, dual-action antibody abelacimab aims to generate hemostasis-preserving anticoagulation by blocking Factor XI.
Where Is the Venous Thromboembolism Market Experiencing the Fastest Regional Growth?
North America was the largest region in the venous thromboembolism market in 2024. The regions covered in venous thromboembolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Get a Customized Version of the Report:
http://www.thebusinessresearchcompany.com/customi…p;type=smp
Leading Players Shaping the Future of the Venous Thromboembolism Industry
Major companies operating in the venous thromboembolism market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S, Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Glenmark Pharmaceuticals Ltd., Portola Pharmaceuticals Inc.
Access the Complete Report:
http://www.thebusinessresearchcompany.com/purchas…x?id=13001
How Our Market Research Reports Help Maximize ROI Across Industries:
* Identify High-Growth Opportunities: Pinpoint emerging trends, untapped segments, and regional hotspots that align with your strategic goals.
* Reduce Investment Risk: Make data-driven decisions with confidence by understanding market dynamics, key drivers, and competitive threats.
* Optimize Strategic Planning: Align your product development, marketing, and expansion plans with industry forecasts and customer behaviour insights.
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
News From
The Business Research Company …
Category: Industry Reports & Market Analysis Profile: The Business Research Company is a leading market research and consulting services provider. It offers over 9,500 market reports across 27 industries in 60+ geographies, providing detailed insights and forecasts. Its customised research solutions support companies in making critical decisions, while its continuous research service enhances organizational capabilities. The flagship Global Market Model database provides comprehensive market intelligence with 1,500,000 datasets covering 8,000+ mark …
This email address is being protected from spambots. You need JavaScript enabled to view it.
